Mirabilis Therapeutics is a drug development company dedicated to the discovery and development of innovative products in the field of cardiovascular diseases and metabolic disorders. Our front running product is indicated against heart failure.
Current treatment options, in particular in the area of diastolic heart failure, are insufficient and indicate an urgent need for disease modifying drugs. The company’s discovery platform has come up with a candidate drug that allows at least for a partial restoration towards a healthy heart and a regain of function, addressing a high medical need with this breakthrough and patented discovery.
Mirabilis Therapeutics has established in vivo proof of concept for its three most advanced antagomirs and multiple follow-on products under evaluation. All this is based on a strong technology and IP position.